Sanofi (NASDAQ: SNY) reported Q3 EPS of EUR2.25, EUR0.88 better than the analyst estimate of EUR1.37. Revenue for the quarter came in at EUR13.44 billion versus the consensus estimate of EUR14.26 billion.

GUIDANCE

On October 21, 2024, the 2024 business EPS(1) guidance was upgraded to growth of at least a low single-digit percentage at CER(2) supported by the underlying strong business performance. This reflects the new scope of guidance excluding Opella detailed in the October 21, 2024 press release. Applying the average October 2024 exchange rates, the currency impact on 2024 business EPS(1) is estimated to be -5.5% to -6.5%.

For earnings history and earnings-related data on Sanofi (SNY) click here.